Skip to main content

S-Equol for Alzheimer's Disease

Recruiting

S-equol is a compound that acts like estrogen in the body and is available as an over-the-counter supplement. In this study, researchers will test the safety and tolerability of a therapeutic dose of S-equol and its effects on cognition in adults with Alzheimer's disease.

Minimum Age Maximum Age Gender Healthy Volunteers
50 Years 90 Years All No
May 5, 2017
November 30, 2020
40

  • Diagnosis of Alzheimer's disease
  • Study partner who has a close relationship and can attend study visits
  • Not a carrier of the APOE 4 gene
  • No medication changes in past 30 days
  • Primary language of English

  • Reside in a nursing home or dementia special care unit
  • Serious medical risk, such as insulin-requiring diabetes, history of cancer that required chemotherapy or radiation therapy within the past 5 years, or heart attack
  • Significant abnormal laboratory values, vital signs, or findings on a physical or neurological exam at screening visit
  • Estrogen or testosterone replacement therapy
  • Participation in another trial or use of an investigational drug or therapy within the past 30 days

Participants will take either a 50 mg S-equol pill or a placebo twice daily for 1 month. Researchers will measure any adverse events, as well as changes in mitochondrial activity, cognitive function, memory, and processing speed.

Name City State Zip Status Primary Contact
Clinical and Translational Science Unit
Fairway Kansas 66205 Recruiting

University of Kansas Medical Center
Kansas City Kansas 66160 Recruiting

Russell Swerdlow, MD

  • Ausio Pharmaceuticals, LLC

Name Role Affiliation
Russell Swerdlow, MD Principal Investigator University of Kansas Medical Center

Name Phone Email
Annette Becker 913-945-7674 abecker@kumc.edu
Rebecca Bothwell 913-945-5033 rbothwell@kumc.edu

NCT03101085

S-Equol in Alzheimer's Disease 2 (SEAD2) Trial